About Event:

This conference offers a holistic understanding of circulating nucleic acids ctDNAcfDNA and ctDNA-cfDNA-based liquid biopsies. It will cover the current and potential utility of these molecules, how they are built into clinical trial designs to inform patient management, and the multiple measurements required to gain the most information from a blood sample. The discussion will feature examples from breast, lung, colorectal, and bladder cancers. We will review the opportunities and challenges of early cancer detection with minimally invasive approaches and scan the near and far horizon for next generation technologies for liquid biopsy. The target audience for this conference is: • senior and junior academic clinicianstrialists • translational scientists • lab analysts and technology developers in academic, pharma, and biotech sectors Deadlines: Abstract submission deadline: 18 November 2024 Registration deadline: 16 December 2024 Speakers: Viktor Adalsteinsson Gerstner Centre for Cancer Diagnostics, USA, Yuval Dor Hebrew University of Jerusalem, Israel, Silvia Marsoni IFOM, Italy, Jeanne Tie Peter MacCallum Cancer Centre, Australia Keywords: cancer research, oncology, circulating tumour DNA, cell-free DNA, liquid biopsy, early cancer detection, clinical trial design, breast cancer, lung cancer, colorectal cancer, bladder cancer, virtual cancer research conference